What is claimed is:

1. Use of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile and pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating immune thrombocytopenia (ITP) in a human patient with persistent or chronic ITP in need thereof, wherein the human patient has an initial platelet count of <30,000/μL with no single platelet count >35,000/μL in the 2 weeks prior to the treatment period, and further wherein the human patient has at least one characteristic chosen from:
    a. a prior response to one or more of IVIG, anti-D, or CSs that was not sustained;
    b. a documented intolerance or insufficient response to any appropriate courses of standard-of-care ITP therapies; and
    c. a contraindication for any appropriate courses of standard-of-care ITP therapies; and

    wherein the medicament is to be administered to the human patient in a therapeutically effective amount twice a day for a treatment period.

2. The use of claim 1, wherein at least one of the following occurs:
    a. the human patient has an initial platelet count of <15,000/μL;
    b. the human patient has an initial platelet count of ≥15,000/μL;
    c. the human patient achieves a platelet response;
    d. the human patient achieves a durable platelet response;
    e. the human patient achieves a complete platelet response;
    f. the human patient achieves a stable platelet response;
    g. the human patient has at least one platelet count of ≥30,000/μL during the treatment period;
    h. the human patient has at least one platelet count of ≥30,000/μL and at least a doubling of the baseline platelet count during the treatment period;
    i. the human patient has at least one platelet count of ≥30,000/μL and at least a doubling of the baseline platelet count in the absence of rescue medication during the treatment period;
    j. the human patient has at least one platelet count of ≥30,000/μL and at least a doubling of the baseline platelet count during a 24-week treatment period;
    k. the human patient has at least one platelet count of ≥30,000/μL and at least a

doubling of the baseline platelet after a 6-month treatment period;

l. the human patient has at least one platelet count ≥50,000/μL during the treatment period;

m. the human patient has at least one platelet count ≥50,000/μL in the absence of rescue medication during the treatment period;

n. the human patient has at least 2 consecutive platelet counts of ≥50,000/μL, wherein the platelet counts are ≥5 days apart, in the absence of rescue medication during the treatment period;

o. the human patient has platelet counts of ≥50,000/μL for at least two-thirds of at least 8 available weekly platelet counts during the last 12 weeks of a 24-week treatment period, further wherein (i) at least 2 available weekly platelet counts are ≥50,000/μL during the last 6 weeks of a 24-week treatment period; and (ii)the human patient does not require rescue medication;

p. the human patient has platelet counts of ≥50,000/μL for at least 8 platelet counts during the last 12 weeks of a 24-week treatment period, further wherein the patient does not require rescue medication;

q. the human patient has no two consecutive platelet counts ≤50,000/μL, wherein the platelet counts occur at least 4 weeks apart within a period of 24 weeks following at least one platelet count of ≥50,000/μL within 12 weeks of initiating rilzabrutinib treatment;

r. the human patient has platelet counts of ≥50,000 for 4 out of the last 8 weeks of a 24-week treatment period;

s. the human patient has platelet counts ≥50,000/μL on ≥4 of 6 biweekly platelet counts between weeks 14 and 24 of a 24-week treatment period;

t. the human patient has platelet counts of ≥50,000 for two-thirds of ≥10 available weekly platelet counts during the last 16 weeks of a 53-week treatment period, further wherein (i) at least 3 available weekly platelet measurements are ≥50,000/μL during the last 8 weeks of the 53-week treatment period; and (ii) the human patient does not require rescue medication;

u. the human patient has:

(i) at least one platelet count ≥50,000/μL; or

(ii) at least one platelet count between ≥30,000/μL and <50,000/μL and at least a doubling of the baseline platelet count;

during a 24-week treatment period in the absence of rescue medication;

v. the human patient has at least one platelet count ≥100,000/μL during the treatment period, wherein the at least one platelet count occurs in the absence of bleeding;

w. the human patient has at least 2 platelet counts of ≥100,000/μL on at least 2 consecutive platelet counts ≥5 days apart in the absence of rescue medication during the treatment period;

x. the human patient has at least one platelet count of ≥250,000/μL during the treatment period;

y. the human patient has at least one platelet count of ≥450,000/μL during the treatment period;

z. the human patient does not require rescue medication during the treatment period;

aa. the human patient has at least one platelet count ranging from 30,000/μL to 100,000/μL during the treatment period, wherein the at least one platelet count is at least double a baseline platelet count and occurs in the absence of bleeding;

bb. the human patient has at least one platelet count ranging from ≥30,000/μL to <50,000/μL and at least a doubling of a baseline platelet count during the treatment period.

3. The use of any one of the preceding claims, wherein at least one of the following occurs:

a. the medicament is to be administered to the human patient with concomitant treatment with TPO-RAs;

b. the medicament is to be administered to the human patient with concomitant treatment with at least one TPO-RA selected from rTPO, romiplostim, eltrombopag, and avatrombopag.

4. The use of any one of the preceding claims, wherein at least one of the following occurs:

a. the human patient has a history of response to at least one prior line of therapy, wherein at least one prior therapy is chosen from a splenectomy, rituximab, TPO-RAs, intravenous immunoglobin (IVIG), corticosteroids, anti-D immunoglobulin

therapy, and immunosuppressive drugs;

b. the human patient had a splenectomy prior to the start of the treatment period;

c. the human patient has a history of taking rituximab prior to the start of the treatment period;

d. the human patient has not received prior treatment with rituximab;

e. the human patient has a history of taking at least one TPO-RA prior to the start of the treatment period;

f. the human patient has a history of taking at least one TPO-RA selected from rTPO, romiplostim, eltrombopag, and avatrombopag prior to the start of the treatment period;

g. the human patient has not received prior treatment with one or more TPO-RAs;

h. the human patient has a history of taking intravenous immunoglobin (IVIG) prior to the start of the treatment period;

i. the human patient has a history of taking at least one corticosteroid prior to the start of the treatment period;

j. the human patient has a history of taking at least one corticosteroid selected from dexamethasone or oral prednisone/prednisolone prior to the start of the treatment period;

k. the human patient has a history of taking anti-D immunoglobulin therapy prior to the start of the treatment period;

l. the human patient has a history of taking at least one immunosuppressive drug prior to the start of the treatment period;

m. the human patient has a history of taking at least one immunosuppressive drug selected from fostamatinib, mycophenolate mofetil (MMF), and cyclosporine prior to the start of the treatment period;

n. the human patient had a response to the prior ITP therapy;

o. the response to the prior ITP therapy comprised a platelet count of <50,000/μL;

n. the response to the prior ITP therapy was not sustained;

q. the human patient has become refractory to at least one prior line of therapy.

5. The use of any one of the preceding claims, wherein at least one of the following occurs:

a. the patient has a documented intolerance to standard-of-care ITP therapies;

b. the human patient has an insufficient response or intolerance to one or more previous treatments.

6. The use of any one of the preceding claims, wherein the patient has a contraindication for standard-of-care ITP therapies.

7. The use of any one of the preceding claims, wherein at least one of the following occurs:

a. the human patient is aged ≥18 years;

b. the human patient is aged <18 years;

c. the human patient is 10 to <18 years of age;

d. the human patient is 12 to <18 years of age;

e. the human patient is 10 to <12 years of age.

8. The use of any one of the preceding claims, wherein at least one of the following occurs:

a. the human patient has had ITP for a duration of >1 year;

b. the human patient has primary ITP;

c. the human patient has relapsing ITP;

d. the human patient has refractory ITP.

9. The use of any one of claims 1-7, wherein the human patient has persistent ITP.

10. The use of any one of claims 1-7, wherein the human patient has chronic ITP.

11. The use of any one of the preceding claims, wherein the treatment period is at least 168 days, at least 364 days, at least 392 days, or at least 728 days.

12. The use of any one of the preceding claims, wherein:

a. the human patient is to be administered 400 mg of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-

d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile and pharmaceutically acceptable salts thereof twice a day; or

b. the human patient is to be administered 400 mg of the at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile and pharmaceutically acceptable salts thereof twice a day; and

i. the at least one compound consists of at least one compound chosen from the (E) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile and pharmaceutically acceptable salts thereof;

ii. the at least one compound consists of at least one compound chosen from the (Z) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile and pharmaceutically acceptable salts thereof; or

iii. the at least one compound consists of a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile or a pharmaceutically acceptable salt of the foregoing.

13. The use of any one of claims 1-11, wherein:

a. the human patient is to be administered 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile twice a day; or

b. the human patient is to be administered 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile twice a day; and

i. the at least one compound is the (E) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile;

ii. the at least one compound is the (Z) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; or

iii. the at least one compound consists of a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

14. The use of any one of the preceding claims, wherein:

a. the medicament is to be orally administered to the human patient;

b. the medicament is to be administered to the human patient in the form of at least one tablet; and/or

c. the medicament is to be administered to the human patient with water.

15. The use of any one of the preceding claims, wherein at least one of the following occurs:

a. the patient experiences a reduction in fatigue;

b. the human patient experiences a reduction in fatigue as determined using ITP Patient Assessment Questionnaire™ (ITP-PAQ™);

c. the human patient experiences a reduction in fatigue as determined using the ITP Kids' ITP Tools (ITP-KIT);

d. the human patient experiences a change from baseline in IBLS at weeks 13 and 15 of a treatment period;

e. the human patient experiences a change from baseline in IBLS at week 25 of a treatment period;

f. the human patient experiences an improvement in quality of life;

g. the human patient experiences an improvement in quality of life as determined by the ITP-KIT;

h. the human patient experiences a change from baseline on the Symptoms, Bother-Physical Health, Activity, Fatigue/Sleep, Psychological Health, Fear, Social Activity, Women's Reproductive Health, and Work domains of the ITP-PAQ™.